Published: 13 February 2020
Author(s): Elisabetta Ricottini, Antonio Nenna, Rosetta Melfi, Sara Giannone, Mario Lusini, Germano Di Sciascio, Massimo Chello, Gian Paolo Ussia, Francesco Grigioni
Issue: July 2020
Section: Original article

The choice of optimal antithrombotic therapy for patients undergoing percutaneous coronary interventions (PCI) with an indication for long-term oral anticoagulation (OAT) is challenging. Atrial fibrillation (AF) is one of most frequent indication for OAT, its prevalence is likely to increase in next decades with aging of world population [1]. Recent data showed an increased prevalence of cardiovascular morbidity among patients with AF [2]. Approximately 5–8% of patients treated with PCI have a concomitant atrial fibrillation (AF) [3,4].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.